October 18, 2019– Rep. Doris Matsui (D-Calif.), a longtime champion of the 340B drug pricing program, defended the program during a key congressional hearing to consider drug pricing legislation. Yesterday’s House Energy & Commerce Committee … [Read More...]
Survey Raises Questions About Duplicate Discounts
Print ArticleOct. 17, 2019– A newly released survey on the interplay of the 340B drug discount program and Medicaid has raised questions about what federal and state rules are in place to prevent duplicate discounts. The bottom line is that several such rules already exist in all 50 states to prevent pharmaceutical manufacturers from paying […]
New Study: No Clinical Evidence Behind U.S. Price Hikes for Costliest Drugs
Print ArticleOctober 15, 2019— The manufacturers of seven widely used drugs raised their prices with no clinical evidence to support those increases, according to a new study by the Institute for Clinical and Economic Review (ICER), an independent research organization. These price hikes added $5.1 billion to the amount Americans spent on prescription drugs between 2017 […]
